Business Overview: Harrow, Inc. (NASDAQ: HROW)

---

Executive Summary

Harrow, Inc., headquartered in Nashville, Tennessee, is an eyecare pharmaceutical company that discovers, develops, and commercializes ophthalmic products for the U.S. market. It operates two complementary lines: a Branded portfolio of FDA-approved ophthalmology drugs, and ImprimisRx, an ophthalmology-focused pharmaceutical compounding business operating since 2014.

Harrow matters because it has built a focused, dual-channel model in ophthalmology — commercializing approved branded drugs while also serving a cash-pay compounding market that bypasses insurance formularies and PBMs entirely, giving it two distinct ways to monetize the same eyecare prescriber relationships.

---

1. Core Business Model & How They Work

Harrow earns revenue by selling FDA-approved branded ophthalmic drugs and by compounding customized ophthalmic formulations sold directly to prescribers and patients on a cash-pay basis.

[ Acquire/License Branded Ophthalmic Drugs ] ➡️ [ Commercialize via Sales Force ] ➡️ [ Collect Branded Revenue ]
[ ImprimisRx Compounding Facilities (503A/503B) ] ➡️ [ Direct Cash-Pay Sales to Prescribers/Patients ] ➡️ [ Collect Compounding Revenue ]

Key operational drivers:

1. Dual-segment model — Branded (FDA-approved drugs, including out-licensed international rights) and ImprimisRx (compounding), evaluated together by the CEO as chief operating decision-maker.
2. Cash-pay compounding niche — ImprimisRx's compounding model explicitly avoids dependence on insurance formularies and PBM reimbursement, a structurally different economic model from the branded business.
3. Equity-stake carve-outs — Harrow has spun out or carved out promising assets into separately capitalized companies (Melt Pharmaceuticals ~45% owned, Surface Ophthalmics ~20% owned) while retaining royalty rights, reducing its own capital burden for early-stage R&D.
4. International out-licensing — in February 2024, Harrow out-licensed Canadian rights to five branded products (VERKAZIA, Cationorm PLUS, VEVYE, ZERVIATE, IHEEZO) to Apotex Inc., monetizing geographies it does not want to commercialize directly.

---

2. Business Segments

┌─────────────────────────┐
│       Harrow, Inc.        │
└────────────┬──────────────┘
             │
   ┌─────────┴──────────┐
   ▼                      ▼
┌───────────┐      ┌─────────────┐
│  Branded   │      │  ImprimisRx │
│ (16 products)│    │ (Compounding)│
└───────────┘      └─────────────┘

Branded

16 U.S. product listings including IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, TOBRADEX ST, ZERVIATE, VERKAZIA, NEVANAC, FRESHKOTE PF, MAXITROL, MAXIDEX, and two IOPIDINE formulations, manufactured by third parties in the U.S., France, and Belgium.

ImprimisRx

Over 30 compounded ophthalmic formulations serving more than 10,000 U.S. eyecare prescribers and institutions, operated through NJOF (an FDA-registered 503B outsourcing facility) and RxNJ (a 503A licensed pharmacy) in Ledgewood, New Jersey.

---

3. Product Portfolio

---

4. Competitive Landscape

Harrow identifies four competitor categories without naming specific companies:

• Branded drug companies — larger ophthalmology-focused pharmaceutical firms.
• Generic drug companies — commoditized alternatives to Harrow's branded products.
• Outsourcing facilities (503B) — other FDA-registered compounders competing directly with NJOF.
• Compounding pharmacies (503A) — other licensed pharmacies competing with RxNJ.

Harrow explicitly acknowledges it is smaller than some competitors and may lack resources to compete for market share, and notes that its compounded (non-FDA-approved) formulations may face physician and patient hesitancy relative to FDA-approved alternatives.

---

5. Strategic Strengths & Risks

Strengths

• Rare dual-channel model spanning both FDA-approved branded drugs and cash-pay compounding gives Harrow two distinct revenue mechanisms within the same ophthalmology prescriber base.
• ImprimisRx's cash-pay model sidesteps PBM/formulary negotiation dynamics that pressure many branded drug makers' margins.
• Disciplined capital allocation — carving out early-stage assets (Melt, Surface Ophthalmics, the prior Eton stake) into separately funded entities while retaining royalty upside reduces Harrow's own R&D cash burn.
• Growing R&D investment ($12.2M in 2024, up from $6.7M in 2023) signals reinvestment into pipeline depth.

Risks

• Section 503A regulatory limits — rules restrict preparing compounded formulations in advance and distributing through wholesalers, a structural constraint FDA-approved competitors do not face.
• Compounded formulations are not FDA-approved, which the company itself flags may make some physicians and patients hesitant to use them versus approved alternatives.
• Smaller scale than larger branded ophthalmology competitors limits Harrow's ability to compete on marketing reach or pricing concessions.
• Reliance on third-party manufacturers (U.S., France, Belgium) for branded products introduces supply-chain and quality-control dependency outside Harrow's direct control.

---

6. Financial Overview

---

7. Summary Conclusion

Harrow has built a genuinely differentiated position in ophthalmology by running both a branded FDA-approved drug business and a cash-pay compounding business (ImprimisRx) side by side, and by using equity carve-outs to fund early-stage pipeline assets without bearing their full R&D cost directly. That structure gives Harrow optionality and capital efficiency a pure branded-only competitor would lack. Its biggest forward risk is regulatory and competitive at once: Section 503A's compounding restrictions constrain how ImprimisRx can operate relative to fully FDA-approved rivals, and Harrow's own disclosed smaller scale versus larger branded ophthalmology competitors means continued execution on both fronts — branded product commercialization and compounding compliance — will determine whether its dual-channel model keeps compounding its advantage or simply spreads it thin.